Golgi apparatus targeted therapy in cancer: Are we there yet?

• Published in: Life Sciences
• Main Author: Lee Z.Y.; Lee W.H.; Lim J.S.; Ali A.A.A.; Loo J.S.E.; Wibowo A.; Mohammat M.F.; Foo J.B.
• Format: Review
• Language: English
• Published: Elsevier Inc. 2024
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85197361707&doi=10.1016%2fj.lfs.2024.122868&partnerID=40&md5=8e6642fd91cbfed7637399307f053a17

Membrane trafficking within the Golgi apparatus plays a pivotal role in the intracellular transportation of lipids and proteins. Dysregulation of this process can give rise to various pathological manifestations, including cancer. Exploiting Golgi defects, cancer cells capitalise on aberrant membrane trafficking to facilitate signal transduction, proliferation, invasion, immune modulation, angiogenesis, and metastasis. Despite the identification of several molecular signalling pathways associated with Golgi abnormalities, there remains a lack of approved drugs specifically targeting cancer cells through the manipulation of the Golgi apparatus. In the initial section of this comprehensive review, the focus is directed towards delineating the abnormal Golgi genes and proteins implicated in carcinogenesis. Subsequently, a thorough examination is conducted on the impact of these variations on Golgi function, encompassing aspects such as vesicular trafficking, glycosylation, autophagy, oxidative mechanisms, and pH alterations. Lastly, the review provides a current update on promising Golgi apparatus-targeted inhibitors undergoing preclinical and/or clinical trials, offering insights into their potential as therapeutic interventions. Significantly more effort is required to advance these potential inhibitors to benefit patients in clinical settings. © 2024 Elsevier Inc.